Open AccessNo Evidence for Decay of the Latent Reservoir in HIV‐1–Infected Patients Receiving Intensive Enfuvirtide‐Containing Antiretroviral Therapy
Author(s) -
Rajesh T. Gandhi,
Ronald J. Bosch,
Evgenia Aga,
Mary Albrecht,
Lisa M. Demeter,
Carrie Dykes,
Barbara Bastow,
Michael F. Para,
Jun Lai,
Robert F. Siliciano,
Janet D. Siliciano,
Joseph J. Eron
Publication year - 2009
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/649569
Subject(s) - enfuvirtide , ritonavir , regimen , medicine , protease inhibitor (pharmacology) , confidence interval , virology , antiretroviral therapy , reverse transcriptase inhibitor , salvage therapy , human immunodeficiency virus (hiv) , pharmacology , immunology , viral load , chemotherapy , gp41 , antigen , epitope
Human immunodeficiency virus type 1 (HIV-1) persists in a latent reservoir of infected resting memory CD4 cells in patients receiving antiretroviral therapy. We assessed whether multitarget therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-boosted protease inhibitor leads to decay of this reservoir. Nineteen treatment-naive patients initiated this regimen; 9 experienced virologic suppression and continued enfuvirtide-containing therapy for at least 48 weeks. In enfuvirtide-treated patients with virological suppression, there was no decay of the latent reservoir (95% confidence interval for half-life, 11 months to infinity). The stability of the latent reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from this reservoir. (ClinicalTrials.gov identifier: NCT00051831 .).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom